Drug Pipeline

Cretostimogene Grenadenorepvec Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
6
Active Studies
3
Recruiting
2
Phase 3
4
Top Sponsors
Active Studies by Phase
Phase 3
2
Phase 2
2
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06111235 A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk… Non Muscle Invasive Bladder Cancer Active, Not Recruiting
NCT04452591 Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer… Non Muscle Invasive Bladder Cancer Active, Not Recruiting
Phase 2
NCT06567743 Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in… High-Risk Non-Muscle-Invasive Bladder Cancer Recruiting
NCT07283835 Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer… Non Muscle Invasive Bladder Cancer Recruiting
Phase 1
NCT07206225 A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer Non-muscle Invasive Bladder Cancer Recruiting
NCT06253845 Study of CG0070 After Transurethral Resection in Patients With IR NMIBC Non-muscle Invasive Bladder Cancer Active, Not Recruiting
Sponsors Running Cretostimogene Grenadenorepvec Trials
CG Oncology, Inc. (3) H. Lee Moffitt Cancer Center and Research Institute (1) Pfizer (1) Lepu Biopharma Co., Ltd. (1)
Disease Areas
Bladder Cancer (6)
Get alerts when Cretostimogene Grenadenorepvec trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free